



an Open Access Journal by MDPI

Kinase Inhibitors from Marine Natural Products

Guest Editor:

Prof. Dr. Se-Kwon Kim

Department of Marine Science &
Convergence Engineering,
Hanyang University, Gyeonggi-do
11558, Republic of Korea

Deadline for manuscript
submissions:

closed (1 October 2020)


Message from the Guest Editor

Seventy percent of the Earth's surface is covered by oceans, which are home to more than seventy percent of living organisms. Sponges, algae, fish species, microorganisms, crustaceans, sea cucumbers, and corals are some of them. These species are resources for potential drugs used for treating various diseases. These organisms are living in extreme conditions, such as different salinity, and lack of nutrients and sunlight; therefore, they can produce potential secondary metabolites. The metabolites/compounds can range from polyphenols, alkaloids, terpenoids, steroids, proteins, lipids, polysaccharides, etc. These compounds can be used as kinase inhibitors and as a cure for several diseases, including the most common and deadly disease—cancer. After finding the metabolic pathways regulating diseases, these kinase inhibitors derived from marine origin molecules can be potentially used to treat several diseases that are involved in protein and lipid kinases.



mdpi.com/si/46708

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)